News Releases

First quarter revenues of $2.37 billion, up 1.5% from 2023 First quarter reported diluted earnings per share ("EPS") of $1.72, down 3.4% from 2023; and adjusted diluted EPS of $2.04, flat with...

Company's AD-Detect™ Portfolio Offers AB 42/40 and Other Plasma Biomarker Testing, Alongside Traditional Cerebrospinal Fluid and Genetic Tests, to Provide Robust Offering in Brain Health...

Leading commercial organizations and patient advocacy groups in the field of cancer genetics today announced the founding of the Inter-Organization Cancer Genetics Clinical Evidence Coalition...

Aim to demonstrate whole genome sequencing can replace the standard diagnostic cascade, for potentially faster diagnosis and lower costs SECAUCUS, N.J., April 2, 2024 /PRNewswire/ -- Quest...

Findings suggest the test can reduce the need for PET imaging in some patients with mild cognitive decline to enable therapeutic focus on non-Alzheimer's disease causes, broadening access to...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2024 financial results on Tuesday, April 23, 2024, before the...

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's...

Grocery Delivery Services Now Available via Instacart to Individuals Participating in the Coaching Programs of Pack Health, a Quest Diagnostics Company, to Mitigate Social Determinants of Health...

Based on technology from SkylineDx, the test aims to aid treatment decisions for patients with the deadliest form of skin cancer Patients classified as low-risk by MelaNodal Predict are shown to...

Directed at individuals who may be at risk of elevated PFAS exposure, the new test detects and measures PFAS identified by National Academies of Sciences, Engineering, and Medicine Organizations...